TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: successful ECV and cephalic presentation at birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of heart failure, lung edema, altered water‐electrolyte balance, ECG abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: postnatal weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of Unstable Angina Pectoris (UAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensation improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Independence improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Visual analogue score for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of pethidine consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative opioid use
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of POCD at 7 days after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: reductions in social anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increases in subjective well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prior cancer screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Belief in screening importance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Conversion to clinically definite multiple sclerosis
Endpoint domain: Mortality/survival
Primary endpoint: Number of active T2-weighted MRI lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: recurrence-free rate for high risk esophageal varices
Endpoint domain: Mortality/survival
Primary endpoint: Efficacy in patients with HCV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability in patients with HCV infection
Endpoint domain: Adverse events/effects
Primary endpoint: mean weekly MET minutes for combined moderate and vigorous activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ICU stay duration
Endpoint domain: Resource use
Endpoint subdomain: ICU
Primary endpoint: reduction in depression rating scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VLDL particle number
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: VLDL size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: reducing alcohol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean duration of sick leave
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: costs associated with productivity losses
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: total brain volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cerebral white matter volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: brainstem volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADAS-cog change scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement in sensory function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ease of injection
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Confidence in managing daily insulin injections
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Preference for teaching and learning
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Usefulness of self-monitoring and dietitian support
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: VAS change from 0 to 120 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Verbal scores at 120 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Additional analgesic requirement after 120 min
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Increase in mouth opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of social anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: risk of a major component of the primary endpoint (SNA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of children reaching normal weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEV1 (PC20) change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Exhaled nitric oxide change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Serum eosinophil cationic protein change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Detection rate of colorectal cancers (CRCs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: anti-HBs response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hospitalization within 72 hours
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in microscopic esophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in average SS from baseline to 1 and 3 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with severe histological changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in hyperkinetic score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in behavior score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung parenchymal assessment quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HSS language score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SADQ-H improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of Mild Cognitive Impairment (MCI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: short-term surgical benefits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean PAED score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of MRI interruption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LMA insertion, removal, and recovery times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: SLT release after stimulation with allergen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Symptom load during pollen season
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage change in LDL-C level at 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Admission Rate (AR)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: mean warning time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median warning time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: minimum warning time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved survival in gastric NHL
Endpoint domain: Mortality/survival
Primary endpoint: pathologic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loss of independence at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Usage of the online nurse reference center
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvement in hepatic fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean 1-year costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Hyoid bone motion during swallowing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Horizontal movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vertical movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement of psychopathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement of interpersonal problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjective experience of symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Treatment effects of paroxetine vs placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improved mood ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Knowledge (KNOW‐PAIN 50)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Attitudes (CAOS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain practice behaviors (PPBS)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: improvement of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Drug injection and syringe sharing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily-life quality scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Nausea intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: RMS of ocular and internal wavefront error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RMS of total and internal high-order aberrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual performance improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: recurrence rate of eczema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: improvement in ear pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of gastric ulcer formation
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical improvements based on WBF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CGI scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of reported radiation sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of PVs remaining isolated 30 minutes after ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total volume of infused saline solution during the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complications observed in TCc group
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative plasma albumin concentration changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 7-day recovery ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative probability of not having relapsed
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative probability of not having consumed any alcohol
Endpoint domain: Mortality/survival
Primary endpoint: Blink frequency score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breakup time of tear film
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Central Macular Thickness (CMT) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient outcome improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total symptom severity complex scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthma Quality of Life Questionnaire overall scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: New peripheral fractures
Endpoint domain: Adverse events/effects
Primary endpoint: Active straight leg raise test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: NOSE scale results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Crust formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: regain of mobility
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Desire for antibiotics
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: haemodynamic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: motor blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Macrophage concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Neutrophil concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: successful resuscitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: time necessary for successful resuscitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: partial pressure of arterial carbon dioxide (PaCO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Understanding of risks and benefits of ACL reconstruction
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: tramadol consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Plasma noradrenaline response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sustained HCV clearance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: negative serum HBV-DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluoroscopy exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean corpuscular hemoglobin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: transferrin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serious bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Soluble transferrin receptor (sTfR) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: supplementary analgesic drug administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of subjects requiring supplementary analgesic drug
Endpoint domain: Adverse events/effects
Primary endpoint: Facial Disability Index (FDI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: House-Brackmann scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent increase of serum IGF-I
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: graft failure requiring revision surgery
Endpoint domain: Adverse events/effects
Primary endpoint: 28-day morbidity rate (multiple organ dysfunction score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ΔE (difference in intensity of darkening)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful robot‐assisted UFE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Median selective target vessel catheterization time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Symptoms relief at 6 months follow‐up
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: acute coronary syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Correct identification of advertisement source
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Renal function preservation or improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Area under the plasma concentration-time curve of ganciclovir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in SF-36 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Global improvement scores on the clinical global impression scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reported adverse events associated with sedative effects
Endpoint domain: Adverse events/effects
Primary endpoint: MGYSS (Meibomian Gland Yielding Secretion Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stimulated salivary flow rate increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: annual morbidity rate
Endpoint domain: Mortality/survival
Primary endpoint: incidence of hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: new/worsened NHND
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Ambulatory Category
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achievement of target levels of LDL cholesterol and triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduced odds of methicillin-susceptible S. aureus presence
Endpoint domain: Adverse events/effects
Primary endpoint: Reduced odds of any S. aureus presence in stool sample
Endpoint domain: Adverse events/effects
Primary endpoint: Functional status enhancement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rehospitalizations
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of gonorrhea
Endpoint domain: Adverse events/effects
Primary endpoint: Continuation of assigned method usage
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rates of physician refusals to allow patient enrollment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvement in symptoms or quality of hearing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tympanometric results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean daily distance walked
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in number of medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monthly medication cost savings
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Age-normalized mean reaction time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Age-normalized errors of commission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: micro-albuminuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: ESWB change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 30-day event rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in passive knee flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventilation success rate under cricoid pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PISA reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean CAL reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Graft dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Clearance of facial atopic dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reversal of skin atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Loss of reconstruction
Endpoint domain: Mortality/survival
Primary endpoint: Hypoperfusion measured by mean transit time (MTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: redistribution of body mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: amelioration of echocardiographic and cardiopulmonary parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: reduction in anxiety, depression, and general psychopathology symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: terminal elimination half-life (t(½β))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lung mean absorption time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time for 90% absorption from the lung
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes